Original news and analysis on international IP policy
The Council of Europe, the 47-member intergovernmental group based in Strasbourg, France, this week adopted an internet governance strategy for the next four years, putting particular emphasis on human rights and democracy online. The strategy includes a series of steps and actions.
The Office of the United States Trade Representative (USTR) today (30 March) issued its annual National Trade Estimate report pointing fingers at trading partners' practices it sees as barriers to US trade. And the treatment of intellectual property in countries like India is high on the list. But the report also goes to lengths to praise progress in countries too.
Five years after its adoption, a World Health Organization mechanism to help the world be ready for future influenza pandemics is being reviewed. According to several stakeholders invited to share their views, a major challenge is genetic sequence data, which allows digital reproduction of material. Other issues include the relationship of the mechanism to an international convention on access to genetic resources, and the contribution of industry.
In light of the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
A number of internet and software industry in the United States have come out in support of the Trans-Pacific Partnership (TPP) negotiated by the Office of the US Trade Representative (USTR) last year.
The leaders of India and the European Council today in Brussels discussed a wide range of topics including intellectual property rights - including geographical indications - innovation, digital issues, and health and pharmaceuticals.
A research group announced in March that it has designed the first minimal synthetic bacterial cell. Rapid advances in science seem to be leaving the international normative process lagging behind. Current international instruments are seeking to understand how this new technology will impact their regulatory efforts, while civil society raises high concerns.
The controversial ruling was perhaps to be expected. The Federal Circuit Court of Appeals doggedly hewed to its existing interpretation of patent law. Unfortunately, the court’s decision in Lexmark International v Impression Products conflicts with recent Supreme Court jurisprudence, according to many experts – thus leaving unresolved some important questions about how much control patentees can maintain over their patented products.
The World Health Organization has released a report on the role of intellectual property in local production of medicines in developing countries. According to the report, the way countries design their intellectual property system is key in the development of local innovation and production. However, health outcomes will depend on the accessibility and affordability of good-quality essential medicines.
Biotherapeutic medicines, engineered by living organisms, have opened a promising path to treat major diseases. Near copies of these medicines, called biosimilars, are slowly coming to market, as the originator products become free of intellectual property rights or data protection.
However, some regulatory issues are left to be addressed, in particular in developing countries, according to the pharmaceutical industry and the World Health Organization. For patients, information on those products and their affordability are key, said a patient group representative.
The new Anton Mostert Chair of Intellectual Property Law at the University of Stellenbosch in South Africa, Professor Sadulla Karjiker, has pointed a finger at the country’s Department of Trade and Industry (DTI) for being “unresponsive” to stakeholders offering their input into proposed IP legislation.
That the Indian government has been under pressure from the United States to change its patent regime is no secret among those who follow the public discourse on intellectual property rights. Now, a new controversy about India’s alleged private assurance to the US-India Business Council (USIBC) and other lobby groups that it would not invoke compulsory licensing for commercial purposes seeks to add fuel to fiery speculation about a shift in India’s policy on IPR.